Commonly reported TRT side effects include a rise in hematocrit (the share of your blood made up of red blood cells), acne or oily skin, ankle swelling, breast tenderness, smaller testicles and a lower sperm count. Injectable products add injection-site reactions. Serious problems such as blood clots or heart rhythm changes are less common. Almost every side effect has a matching check, such as a blood test, blood pressure reading or sleep history.

Key takeaways

TRT side effects at a glance: common, serious and the check that catches each

Most TRT side effects fall into two groups. Some you notice yourself, like acne or ankle swelling. Others, like hematocrit, blood pressure and PSA (prostate-specific antigen, a blood marker made by the prostate), only show up when someone measures them.

The label details here come from specific FDA-approved testosterone products. They describe those products, not any particular pathway.

Side effectWhat the evidence saysWhat catches it
Rise in hematocritOne of the common adverse effectsHematocrit test before and during treatment
Injection-site redness or reactionMost common reactions (4% or more) on one injectable labelWhat you see and report
Acne, oily skin, ankle swellingListed side effectsSymptom report and exam
Breast tenderness or enlargement (gynecomastia)Listed side effectSymptom report and exam
Smaller testicles, lower sperm countListed side effectsFertility history before starting
Higher PSA, urinary symptomsAverage PSA rise reportedPSA test and urinary symptom questions
Higher blood pressureLabel warningPeriodic blood pressure readings
Worse sleep apneaLabel warning for people with risk factorsSleep history and screening
Headache, mood or libido changesListed in labelsSymptom review
Pulmonary embolism, atrial fibrillation, priapism (a prolonged erection)Less common; see the heart and clot sectionUrgent symptoms that need emergency care

Why does TRT raise hematocrit, and why is it watched so closely?

Testosterone pushes the bone marrow to make more red blood cells. Too many can thicken the blood and raise clotting risk, so hematocrit is checked before and during treatment.

A 2025 narrative review calls erythrocytosis (a red cell count that runs too high) one of the common adverse effects of TRT and says it raises clotting risk (Int Braz J Urol, 2025). The Endocrine Society guideline defines erythrocytosis on testosterone as a hematocrit above 54% (Endocrine Society, 2018). The review says phlebotomy (removing blood) is indicated above 52% (Int Braz J Urol, 2025). These thresholds are written for clinicians, not as personal targets.

Labels set the basic checks. One testosterone cypionate label says to confirm hematocrit is not elevated before starting, monitor it periodically and discontinue if necessary (AZMIRO label, 2025). One enanthate label says to monitor it approximately every 3 months (XYOSTED label, 2025). The guideline adds a standardized monitoring plan (Endocrine Society, 2018):

  1. Review symptoms, side effects and adherence.
  2. Measure testosterone and hematocrit at 3 to 6 months, depending on the formulation, and again at 12 months.
  3. Evaluate prostate cancer risk during the first year.

Baseline tests may include two morning testosterone tests, hemoglobin, hematocrit, liver function, LH (luteinizing hormone, a pituitary signal to the testes), PSA and prolactin (Cleveland Clinic, 2025). If hematocrit climbs, your clinician decides what happens next. Our TRT blood work guide explains each test.

Injectable vs gel testosterone side effects: does the form matter?

Somewhat, but less than many people assume. Every form studied raises hematocrit, and intramuscular injections of enanthate or cypionate raised it more than patches.

That finding comes from a 2022 network meta-analysis (a method that compares treatments across many trials at once) of 29 placebo-controlled randomized trials and 3,393 men. No other pair of forms differed significantly, head-to-head trials are rare, and the authors say the clinical meaning of the rise is still unclear (J Urol, 2022).

FormHematocrit findingForm-specific note
Intramuscular enanthate or cypionateLarger rise than patch; about 4.0% in the 2025 reviewInjection-site redness and reaction
Oral testosterone undecanoateAbout 4.3% in the 2025 reviewNone listed in these sources; the review's liver caution concerns older oral forms
GelRaised versus placebo; no significant difference from other formsSkin irritation with topicals
Patch or nasal gelMore modest rises in the 2025 reviewSkin irritation with patches

Sources: J Urol, 2022; Int Braz J Urol, 2025; AZMIRO label, 2025; Cleveland Clinic, 2025.

TRAVERSE, a large randomized safety trial (covered below), tested a gel, so its findings do not automatically apply to injections (NEJM, 2023). The guideline says choosing a formulation should weigh its specific adverse effects and the patient's preference (Endocrine Society, 2018). That choice belongs to a licensed clinician, based on your history and labs.

TRT blood pressure, heart and clot risk

Testosterone can raise blood pressure, and current labels warn about it. In TRAVERSE, testosterone gel did not increase major cardiac events, but pulmonary embolism, atrial fibrillation and acute kidney injury were more common.

A July 2025 revision to one testosterone cypionate label added or revised warnings on blood pressure increases and venous thromboembolism (blood clots in the veins), and removed the older Cardiovascular Risk section (AZMIRO label, 2025). One injectable enanthate product carries a boxed warning that testosterone can raise blood pressure, and its label says it is not recommended for men with uncontrolled hypertension (XYOSTED label, 2025).

TRAVERSE was a randomized, placebo-controlled trial of 5,198 men with low testosterone and existing heart disease or high cardiovascular risk (NEJM, 2023). It tracked major adverse cardiac events, a combined count of serious events such as heart attack and stroke:

The trial used a gel, averaged about 21.7 months of treatment and enrolled men at elevated cardiovascular risk, so it answers one question for one form in one population. Our TRAVERSE trial breakdown covers the details.

Labels also note reported blood clots, including deep vein thrombosis, and possible edema (swelling from fluid buildup) in men with existing heart, kidney or liver disease (XYOSTED label, 2025).

Prostate, sleep apnea and sperm: what gets screened before starting

Prostate findings, untreated severe sleep apnea and plans to have children soon can each decide whether TRT is appropriate at all.

Testosterone is contraindicated with known or suspected prostate cancer or male breast cancer (XYOSTED label, 2025). The 2025 review reports an average PSA rise of 0.30 ng/mL on TRT, and 0.43 ng/mL in older men (Int Braz J Urol, 2025). The guideline advises against starting with a palpable prostate nodule or a PSA above 4 ng/mL (above 3 ng/mL in men at higher risk) without further urological evaluation (Endocrine Society, 2018).

Sleep apnea can get worse on testosterone, especially in people with risk factors (AZMIRO label, 2025). The guideline advises against starting with untreated severe obstructive sleep apnea (Endocrine Society, 2018). Our guide to TRT and sleep apnea risk has the full evidence.

Sperm production can fall on TRT. TRT can shut down the testes' own production, which has to recover after treatment stops (Cleveland Clinic, 2025). Labels warn that androgens may cause azoospermia, meaning no sperm in the semen (XYOSTED label, 2025). Recovery takes time and can't be promised. The guideline advises against starting testosterone in men planning fertility in the near term (Endocrine Society, 2018), so raise fertility plans at the first visit. Our article on how TRT affects fertility covers recovery and the options clinicians discuss.

When should you contact a clinician about TRT side effects?

Possible blood clot symptoms or an erection that won't go down need emergency care. Other new or changing symptoms should go to your clinician, without stopping or changing treatment on your own.

Call 911 or go to an emergency room for:

Labels say anyone with signs of a deep vein clot or pulmonary embolism should be evaluated (XYOSTED label, 2025). Telehealth is not for emergencies.

Message or call your clinician about:

Follow your clinician's guidance and the pharmacy instructions, and decide any changes together.

How access works through New Blue

Every testosterone pathway at New Blue, including the injectable protocol, requires a live clinician visit plus lab work. None of them is a quick online form.

  1. You complete an intake covering your symptoms, history, sleep, fertility plans and medications.
  2. You have a live visit with a licensed clinician and complete lab work.
  3. The clinician decides whether testosterone is appropriate based on your intake, labs and clinical review. Not everyone qualifies, and that's how it should work.
  4. If prescribed, a licensed partner pharmacy ships the medication directly to you. Ongoing labs and follow-up are part of care.

New Blue is a technology and administrative services platform. Medical services are provided by independent licensed clinicians; medications are dispensed only if prescribed. Care is for adults 21 and older and is not for emergencies. Consultation timing varies by clinician availability. Availability varies by state, so check state availability. For current pricing, see the injectable testosterone protocol page. If treatment isn't appropriate, refunds follow our refund policy.

Frequently Asked Questions

Is thick blood on TRT dangerous?

A high hematocrit makes blood thicker, and a 2025 review links it to higher clotting risk. Labels and the Endocrine Society guideline call for checking hematocrit before starting and during treatment. If it rises, a clinician decides whether to pause or adjust treatment.

Are testosterone injections riskier than gel?

Not clearly. In a 2022 network meta-analysis of randomized trials, injections raised hematocrit more than patches, but gel did not differ significantly from injections. The large TRAVERSE safety trial tested a gel, so its results don't transfer automatically to injections, and the right form is a clinical decision.

Does TRT affect fertility?

Yes, it can. TRT can lower sperm count, and recovery after stopping takes time and can't be promised. The Endocrine Society guideline advises against starting testosterone in men planning fertility in the near term.

Does TRT cause heart attacks?

In the TRAVERSE trial, testosterone gel did not increase major adverse cardiac events compared with placebo, though pulmonary embolism and atrial fibrillation were more common. The trial studied gel in men at high cardiovascular risk, so it does not settle the question for every form or every man.

Does TRT cause prostate cancer?

A 2025 review found no significant prostate cancer concern in closely monitored men, though PSA tends to rise modestly. Testosterone is contraindicated with known or suspected prostate cancer, and an elevated PSA or a prostate nodule calls for urological evaluation before starting.

How often are labs checked on TRT?

The Endocrine Society guideline describes checking testosterone and hematocrit at 3 to 6 months, depending on the formulation, and again at 12 months. Your clinician sets your own schedule.

Sources

  1. AZMIRO (testosterone cypionate) injection: Drug Label Information. DailyMed, U.S. National Library of Medicine, 2025.
  2. XYOSTED (testosterone enanthate) injection: Highlights of Prescribing Information. U.S. Food and Drug Administration, 2025.
  3. Label: Testosterone Cypionate injection. DailyMed, U.S. National Library of Medicine, 2025.
  4. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology and Metabolism, 2018.
  5. Cardiovascular Safety of Testosterone-Replacement Therapy. The New England Journal of Medicine, 2023.
  6. Management of Adverse Effects in Testosterone Replacement Therapy. International Brazilian Journal of Urology, 2025.
  7. The Effect of Route of Testosterone on Changes in Hematocrit: A Systematic Review and Bayesian Network Meta-Analysis of Randomized Trials. Journal of Urology, 2022.
  8. Testosterone Replacement Therapy (TRT). Cleveland Clinic, 2025.

Medical disclaimer: This article is educational and is not medical advice. Treatment decisions are made by a licensed clinician based on your history, labs and clinical review. New Blue Health is a technology and administrative services platform, not a medical provider.

Related treatment guide

Related reading

Content review & editorial standards

This page is educational content from the New Blue Health Editorial Team. It is checked under the New Blue Health Content Review Policy and Editorial Policy and should not replace individualized medical advice from a licensed clinician. For how we evaluate evidence, see Evidence Methodology and Clinical Sources & References.

Start Your Visit